139 related articles for article (PubMed ID: 36345231)
1. Commentary on the European Medicines Agency's extended mandate: Protecting public health in times of crisis and improving availability of medicines and medical devices.
Abed I; Gonzalez-Quevedo R; Mura M; Dias M; da Rocha Dias S; García Burgos J
Br J Clin Pharmacol; 2023 Jan; 89(1):5-10. PubMed ID: 36345231
[No Abstract] [Full Text] [Related]
2. A future for regulatory science in the European Union: the European Medicines Agency's strategy.
Hines PA; Janssens R; Gonzalez-Quevedo R; Lambert AIOM; Humphreys AJ
Nat Rev Drug Discov; 2020 May; 19(5):293-294. PubMed ID: 32235873
[No Abstract] [Full Text] [Related]
3. The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines.
Cavaleri M; Enzmann H; Straus S; Cooke E
Lancet; 2021 Jan; 397(10272):355-357. PubMed ID: 33453149
[No Abstract] [Full Text] [Related]
4. The European Medicines Agency's goals for regulatory science to 2025.
Hines PA; Guy RH; Humphreys AJ; Papaluca-Amati M
Nat Rev Drug Discov; 2019 Jun; 18(6):403-404. PubMed ID: 31160761
[No Abstract] [Full Text] [Related]
5. The European Medicines Agency's plans for sharing data from clinical trials.
Groves T; Godlee F
BMJ; 2013 May; 346():f2961. PubMed ID: 23657192
[No Abstract] [Full Text] [Related]
6. Preparing Europe for future health threats and crises ─ the European Medicines Agency; ensuring safe and effective medicines and medical devices.
Cooke E
Euro Surveill; 2022 Oct; 27(42):. PubMed ID: 36268739
[No Abstract] [Full Text] [Related]
7. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance.
Permanand G; Mossialos E; McKee M
Clin Med (Lond); 2006; 6(1):87-90. PubMed ID: 16521363
[TBL] [Abstract][Full Text] [Related]
8. Euro MPs refuse to approve medicines agency's accounts until they tighten rules on conflicts of interest.
Watson R
BMJ; 2012 May; 344():e3495. PubMed ID: 22597355
[No Abstract] [Full Text] [Related]
9. [The Medical Product Agency's work and economics--a comment].
Ahlqvist Rastad J; Salmonson T
Lakartidningen; 2003 Jan; 100(5):345. PubMed ID: 12607382
[No Abstract] [Full Text] [Related]
10. Drug policy for an aging population--the European Medicines Agency's geriatric medicines strategy.
Cerreta F; Eichler HG; Rasi G
N Engl J Med; 2012 Nov; 367(21):1972-4. PubMed ID: 23171092
[No Abstract] [Full Text] [Related]
11. [The Medical Products Agency's preparations prior to the new EU regulation on children and drugs].
Johannesson M; Berglund EG
Lakartidningen; 2007 Jul 11-24; 104(28-29):2099. PubMed ID: 17702388
[No Abstract] [Full Text] [Related]
12. Regulation of medicines and medical devices: contrasts and similarities.
Parvizi N; Woods K
Clin Med (Lond); 2014 Feb; 14(1):6-12. PubMed ID: 24532735
[TBL] [Abstract][Full Text] [Related]
13. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
van Luijn JC; Gribnau FW; Leufkens HG
Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187
[TBL] [Abstract][Full Text] [Related]
14. Specialists attack drug agency's fast track approval scheme.
Hawkes N
BMJ; 2016 Jun; 353():i3060. PubMed ID: 27251150
[No Abstract] [Full Text] [Related]
15. The European Medicines Agency's strategies to meet the challenges of Alzheimer disease.
Haas M; Mantua V; Haberkamp M; Pani L; Isaac M; Butlen-Ducuing F; Vamvakas S; Broich K
Nat Rev Drug Discov; 2015 Apr; 14(4):221-2. PubMed ID: 25829266
[TBL] [Abstract][Full Text] [Related]
16. Overview of the European Medicines Agency's Experience With Biowaivers in Centralized Applications.
Lenić I; Blake K; Garcia-Arieta A; Potthast H; Welink J
Clin Transl Sci; 2019 Sep; 12(5):490-496. PubMed ID: 31046182
[TBL] [Abstract][Full Text] [Related]
17. Transparency interrupted: the curtailment of the European Medicines Agency's Policy on access to documents.
Doshi P
JAMA Intern Med; 2013 Nov; 173(21):2009-11. PubMed ID: 23959623
[No Abstract] [Full Text] [Related]
18. The European Medicines Agency's approval of new medicines for type 2 diabetes.
Blind E; Janssen H; Dunder K; de Graeff PA
Diabetes Obes Metab; 2018 Sep; 20(9):2059-2063. PubMed ID: 29740935
[TBL] [Abstract][Full Text] [Related]
19. CardioPulse: The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors.
Blind E; de Graeff PA; Meurs I; Holtkamp F; Baczynska A; Janssen H
Eur Heart J; 2016 Feb; 37(6):502-3. PubMed ID: 26853264
[No Abstract] [Full Text] [Related]
20. Top adviser at the European Medicines Agency quits suddenly.
Benkimoun P
BMJ; 2012 Apr; 344():e2641. PubMed ID: 22496308
[No Abstract] [Full Text] [Related]
[Next] [New Search]
